


Introduction:

Bharat Biotech International Limited is a multidimensional biotechnology company specializing in product-oriented research, development and manufacturing of vaccines and biotherapeutics. Bharat Biotech was established in the year 1996 by Dr. Krishna M. Ella & Mrs. Suchitra K. Ella, and is one of the largest manufacturers of INDIRAB® (anti rabies vaccine) in India. Bharat Biotech is a WHO prequalified manufacturer of REVAC-B® (Hepatitis-B vaccine) for supply to UNICEF and the only vaccine company in India to manufacture and supply a preservative (Thiomersol) free vaccine, REVAC-Bmcf®.

Business Model:

Bharat Biotech has developed a 3 dimensional business model with emphasis on Biogenerics, Contract Manufacturing & Research and Novel products. This strategy has given Bharat Biotech the ability to earn revenues in the short and medium term while focusing on novel patent protected products for the long term, much needed by the developing world.


Commercial Products:

Vaccines	Description
INDIRAB®	Anti Rabies vaccine, chromatographically purified,
REVAC-B mcf®	Tiomersol (Mercury free) and Cesium chloride free Hepatitis B vaccine,
REVAC-B™	WHO Prequalified Hepatitis B vaccine,
BIOHIB®	Haemophilus Influenza B vaccine,
COMVAC5®	Combination vaccine containing DPT+HepB+Hib,
BIOPOLIO®	Oral Polio vaccine, monovalent and trivalent,
TYPBAR™	Vi polysaccharide Typhoid vaccine,
Bio-Therapeutics	Description
REGEN-D®	Wound healing epidermal growth factor for diabetic foot ulcers, Burns, skin grafts,
BIOGIT®	Probiotic Yeast for antibiotic induced and travelers diarrhea,
ZELECT®	Oral Rehydration therapy with Zinc,

1. **REVAC-B mcf®**: First Hepatitis B vaccine in the World 100% free of Mercury and Cesium Chloride, patent protected,
2. **INDIRAB®**: One of India's largest manufacturers of Anti Rabies vaccine, patent protected,
3. **BIOPOLIO®**: One of the largest supplier of oral polio vaccines to Govt of India,
4. **REGEN-D®**: First product approved in India for wound healing in Diabetic foot ulcers and Burns, patent protected,

Research & Development; Product Pipeline, Partnerships:

Bharat Biotech's vision has been to generate innovative technologies with strong backbone of intellectual capital, for manufacturing of unique biopharmaceuticals and vaccines with global IPR associated with the products. Bharat Biotech has been granted a number for patents for new technologies for vaccines and therapeutics, staying true to our mission to develop novel technologies to address the health care needs of the developing world. Bharat Biotech is working hard to develop these novel technologies and commercialize them by working on vaccines and therapeutics against Rotavirus diarrhea, Malaria, Japanese Encephalitis, Staph Aureus etc.

Product	Description	Status
ORV 116E¹	Oral rotavirus vaccine,	Phase II clinical trials
PvRII²	Malaria vaccine,	Pre clinical studies
Lysostaphin	Anti Staphylococcus aureus Therapeutic, anti infective against MRSA,	Phase I-II clinical trials, PRE-IND in USFDA,
Typhoid-TT Conjugate	Vi polysaccharide- Tetanus conjugate vaccine	Phase I clinical studies
Staph Aureus vaccine	Anti Staphylococcus aureus vaccine	Pre clinical studies
THR-100³	Novel variant of Staphylokinase, against heart attack,	Phase II clinical trials
REGEN-D®	r-Epidermal Growth Factor for Diabetic Foot ulcers and Burns,	Pre-IND in USA,

1. Partnership with Department of Biotechnology, Government of India; PATH; US Centers for Disease Control and Prevention (CDC); Stanford University; US National Institutes of Health, National Institute of Allergy and Infectious Diseases (NIAID); Society for Applied Studies; National Institute of Immunology, New Delhi; Indo-US Vaccine Action Program; and All India Institute of Medical Sciences.

2. Partnership with ICGEB, PATH and Department of Biotechnology, Government of India.
3. Partnership with Thrombogenics NV,

Bharat Biotech has shown significant progress in new product development and has partnered with companies from USA and Europe to co-develop, manufacture and market these products. Bharat Biotech has built productive partnerships with companies, such as Wyeth, Agennix, etc due to its manufacturing expertise, new product development experience and respect for global IPR. Bharat Biotech is one of the first companies in India to perform contract manufacturing of vaccines for MNC's such as Wyeth, due to the IPR associated with its Hib vaccine.

Manufacturing and Control

Bharat Biotech has made significant strides in manufacturing and commercializing vaccines for immunization programs, worldwide. **Bharat Biotech is a prequalified supplier of Hepatitis B vaccine to UNICEF and other global procurement agencies.** Manufacturing, Control Procedures and Protocols, conform to stringent standards laid down by internationally recognized institutions such as USFDA, UKMCA and WHO. It is the first bio-pharma company in India to be **audited and approved by Korean Food & Drugs Administration (KFDA) for the manufacture of an injectable.**

These products, technologies, collaborations and partnerships help Bharat Biotech strive to achieve its mission to develop novel health care technologies for the developing world, without violating IPR.